Farber Disease

Farber Disease

Table of Contents

Other names

  • Acid ceramidase deficiency
  • Farber disease
  • Farber lipogranulomatosis
  • Acylsphingosine deacylase deficiency
  • Ceramidase deficiency
  • Farber-Uzman syndrome

In vitro fertilization (IVF) and preimplantation genetic testing (PGT) are significant advancements in the realm of reproductive medicine and genetics, particularly for individuals at risk of transmitting genetic disorders like Farber Disease. For couples with a known risk of passing on Farber Disease to their offspring, IVF coupled with PGT offers a proactive approach. In this process, eggs are fertilized in a lab setting, and the resulting embryos are screened for the specific genetic mutations associated with Farber Disease. This enables the selection of embryos without the disorder for implantation, significantly reducing the likelihood of the child inheriting Farber Disease. Thus, IVF and PGT provide a powerful combination for family planning, particularly for those with a genetic predisposition to this condition, allowing them to minimize the risk of genetic transmission while achieving pregnancy.


ASAH1-related disorders belong to the family of hereditary metabolic diseases known as lysosomal storage disorders (LSDs). Among these is Farber’s disease, also recognized as Farber’s lipogranulomatosis, a rare condition within the broader category of inherited lipid storage diseases. This disorder is characterized by the abnormal accumulation of lipids – such as oils, fatty acids, and similar compounds – to detrimental levels, predominantly affecting the central nervous system, joints, and various tissues. Critical organs like the liver, heart, and kidneys might also suffer from these excessive lipid levels. The root cause of Farber’s disease is a deficiency in an enzyme known as ceramidase.

Patients with Farber lipogranulomatosis typically exhibit three hallmark symptoms: a distinctively hoarse voice or a feeble cry in infancy, the formation of small fatty lumps under the skin and in other tissues (known as lipogranulomas), and the presence of swollen, painful joints. These signs usually begin to manifest early in life, during infancy.

Individuals affected by Farber lipogranulomatosis often experience an enlargement of the liver and spleen, as well as an increase in the size of immune system tissues, a result of substantial lipid deposits. These deposits can extend to the eyes and lungs, potentially leading to complications with vision and respiratory functions. Additionally, patients may experience progressive osteoporosis, a condition that leads to the thinning of the bones and intensifies over time.


Approximately 200 cases of Farber disease have been reported worldwide.


Farber disease exhibits a broad spectrum of clinical variability among patients. The classic form typically emerges between 3-6 months of age, characterized by painful, swollen, and stiff joints in the hands and feet, noticeable subcutaneous nodules over pressure points, and progressive hoarseness that can lead to complete loss of voice (aphonia) due to vocal cord infiltration. In addition to these, patients may experience complications in cardiac, pulmonary, and neurological systems. Some forms of the disease show marked neurological decline, including seizures, paraparesis, and developmental delays. The most severe neonatal variant presents at birth with symptoms like hydrops fetalis, lethargy, failure to thrive, and rapid neurological decline, accompanied by hepatosplenomegaly and granulomatous infiltrations in various organs such as the liver, spleen, and lungs. However, milder forms have also been identified, exhibiting no neurological defects and allowing for a longer lifespan. In certain cases, the disease manifests during childhood as spinal muscular atrophy associated with progressive myoclonic epilepsy (SMA-PME), without the presence of subcutaneous nodules.

The most common symptoms of Farber disease include joint disease causing pain and movement difficulties, subcutaneous nodules (especially on hands, feet, and head), and a hoarse or weak voice due to vocal cord issues. These symptoms vary in appearance and severity, with other possible symptoms including respiratory difficulties, persistent pain, recurrent fever, systemic inflammation, failure to thrive, abnormal bone development, developmental delays, muscle and brain disease, liver and/or spleen enlargement, and eye changes.

The progression and severity of Farber disease differ greatly among patients. Severe cases in infants can lead to rapid symptom development and early death, while other individuals with the disease may experience delayed symptom onset and live into adulthood. Due to its diverse manifestations, Farber disease is often misdiagnosed as juvenile idiopathic arthritis (JIA) or other arthritis types.


ASAH1-related disorders are the result of genetic mutations in the ASAH1 gene. Genes are vital for creating proteins that have essential roles in numerous bodily functions. When there is a mutation in a gene, the resulting protein may be defective, inefficient, nonexistent, or produced in excess. The impact of such a mutation depends on the specific role of the protein, potentially affecting various organ systems within the body.

The ASAH1 gene is responsible for encoding an enzyme known as acid ceramidase. This enzyme plays a crucial role in the breakdown (hydrolysis) of a group of fatty substances called ceramides. Ceramides, which are diverse and exist in various forms within cells, are important for many normal cellular functions. In individuals with ASAH1-related disorders, due to the genetic alteration, the activity of the acid ceramidase enzyme is significantly reduced. This leads to the abnormal accumulation of ceramides in different organ systems, causing damage to those areas. The specific location and extent of ceramide buildup can vary, leading to the diverse manifestations of the disorder in affected individuals.

Variations in the ASAH1 gene lead to a significant reduction in the enzyme acid ceramidase, often falling to less than 10 percent of the normal level. This drastic decrease means the enzyme is largely unable to effectively break down ceramides. Consequently, these ceramides accumulate in the lysosomes of various cell types, including those in the lungs, liver, colon, skeletal muscles, cartilage, and bone. The accumulation of ceramides, coupled with a reduction in their fatty acid breakdown products within the cells, is believed to be the underlying cause of the symptoms observed in Farber lipogranulomatosis. However, it remains uncertain whether the degree of acid ceramidase activity directly correlates with the severity of the disorder. This lack of clarity means that predicting the progression and impact of the disease based on enzyme levels alone is challenging.


ASAH1-related disorders are passed down through an autosomal recessive inheritance pattern. In genetics, the traits an individual inherits are determined by the genes present on the chromosomes received from both parents. In recessive genetic disorders, the condition manifests when a person inherits two mutated genes for the same trait, one from each parent.

If an individual inherits one normal gene and one mutated gene for the disorder, they become a carrier of the disease. These carriers usually do not exhibit symptoms of the disease themselves. For two carrier parents, the probability of passing on the defective gene and thus having a child affected by the disorder is 25% for each pregnancy. There is also a 50% chance with each pregnancy that the child will inherit one normal gene and one defective gene, making them a carrier like the parents. Additionally, there is a 25% chance for each pregnancy that the child will inherit two normal genes, making them genetically unaffected by the trait in question. This risk is the same regardless of the child’s sex.

In summary, each child of parents who are both carriers of the mutated gene has a one in four chance of being affected by the disorder, a two in four chance of being a carrier, and a one in four chance of being genetically unaffected.

Diagnostic methods

The diagnosis of ASAH1-related disorders relies on a combination of clinical assessments and laboratory investigations. Key diagnostic methods include:

  1. Enzyme Activity Assays: Testing for the activity of acid ceramidase in peripheral blood leukocytes, cultured lymphoid cells, or cultured skin fibroblasts. This is a crucial step as it directly measures the functionality of the enzyme implicated in the disorder.
  2. Ceramide Concentration Measurement: Determining the concentration of ceramides in cultured cells or tissues, or assessing lysosomal ceramide catabolism in living cultured cells, can provide important diagnostic information, given the role of ceramide accumulation in the disease.
  3. Molecular Genetic Testing: Identifying mutations in the ASAH1 gene through molecular genetic testing typically confirms the diagnosis. This test can be conducted using blood samples or, in prenatal cases, amniotic fluid.
  4. Prenatal Diagnosis: For families with a known disease-causing mutation, prenatal diagnosis is possible through DNA testing. Alternatively, prenatal diagnosis can also be carried out by measuring acid ceramidase activity in cultured amniotic fluid cells or chorionic villi.

The diagnostic process includes:

A Thorough History: Gathering comprehensive medical and family history information.

Clinical Examination: A detailed physical examination to identify symptoms and signs consistent with the disorder.

Plasma Ceramidase Enzyme Activity Testing: A blood test to measure the activity level of the enzyme.

Genetic Testing: Conducted to detect mutations in the ASAH1 gene, using blood samples or, for prenatal diagnosis, amniotic fluid.

These diagnostic methods combined help in accurately identifying and confirming ASAH1-related disorders.


Certain disorders exhibit symptoms similar to those seen in ASAH1-related disorders, making differential diagnosis important. Some of these include:

  1. Lysosomal Storage Disorders: This category encompasses various disorders, among which Sandhoff disease is particularly notable. Like ASAH1-related disorders, lysosomal storage disorders involve the accumulation of substances within the lysosomes due to enzyme deficiencies or malfunctions. Sandhoff disease, specifically, shares similarities in terms of neurological symptoms and organ involvement.
  2. Juvenile Idiopathic Arthritis (JIA): This is a type of arthritis that occurs in children. It is characterized by joint swelling, pain, and stiffness, symptoms that are also common in ASAH1-related disorders. However, JIA does not typically involve the wide range of systemic symptoms seen in ASAH1-related disorders, such as organ involvement and neurological issues.

Differentiating between these disorders is crucial for accurate diagnosis and appropriate treatment. This often requires a combination of clinical evaluation, laboratory tests, genetic testing, and enzyme activity assays. Each disorder, while sharing some overlapping symptoms, has distinct features and underlying causes that guide the diagnostic process.

Differential diagnosis

When diagnosing ASAH1-related disorders, it’s important to consider and exclude several other conditions that have overlapping symptoms. The differential diagnoses include:

  1. Juvenile Idiopathic Arthritis (JIA): This condition primarily affects the joints, causing symptoms like swelling, pain, and stiffness, which are also observed in ASAH1-related disorders. However, JIA typically does not involve the systemic symptoms such as organ involvement and neurological issues that are seen in ASAH1-related disorders.
  2. Stiff Skin Syndrome: This rare dermatological condition is characterized by hard, thick skin that can limit joint mobility. It might be considered in the differential diagnosis due to its impact on joint movement and skin abnormalities, which could be mistaken for symptoms of ASAH1-related disorders.
  3. Lethal Restrictive Dermopathy: A severe, inherited skin disorder, lethal restrictive dermopathy is marked by tight and rigid skin, leading to restricted movement and developmental issues. The skin symptoms might overlap with some cutaneous manifestations of ASAH1-related disorders.
  4. Encephalopathy due to Prosaposin Deficiency: This is a rare condition affecting the brain. Since ASAH1-related disorders can also have neurological symptoms, including encephalopathy, it is important to differentiate between these two conditions.

Each of these differential diagnoses has distinct clinical and diagnostic features. Accurate diagnosis often requires a comprehensive approach, including detailed clinical evaluations, laboratory tests, imaging studies, and genetic testing. This ensures that the correct condition is identified and that appropriate treatment and management strategies are employed.

Genetic counseling

In cases of ASAH1-related disorders, which follow an autosomal recessive pattern of inheritance, genetic counseling plays a crucial role for affected families. This counseling is essential to provide clear information about the risks and implications of the disorder’s transmission. It also offers support in dealing with the emotional and psychological aspects of having a child with a genetic disorder or being at risk of having one. This counseling is vital in helping families make informed decisions and prepare for the various outcomes associated with the genetic risk.

Management and treatment

As of now, there is no specific cure for Farber disease. Treatment focuses on managing symptoms and may include:

Analgesics and Corticotherapy: For pain and inflammation management.

Plastic Surgery: To address certain physical manifestations of the disease.

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT): Showing promise, particularly for patients with limited neurological involvement.

Anti-Epileptics: For seizure control.

Surgery: Including removal of airway or mouth nodules, tracheostomy for breathing issues, and gastrostomy tube insertion for nutritional support.

Anti-Inflammatory Medications: To manage joint disease.

Respiratory Therapy: For managing breathing difficulties and recurrent pneumonia.

Assistive Devices: Such as special shoes, walkers, or wheelchairs for mobility assistance.

Additionally, ongoing research into gene therapy offers potential future treatment options. This approach involves supplementing the defective gene with a normal one to enable the production of the active enzyme, aiming for a sustained correction of the disease.

Patients who have undergone HSCT, a procedure to replace the bone marrow with healthy marrow from a donor, have shown improvement in skin and joint problems associated with Farber disease.

Comprehensive care for Farber disease also includes genetic counseling for affected individuals and their families, as well as psychosocial support, given the significant impact of the disorder on the patient and family members.


The prognosis for children with Farber’s disease varies significantly depending on the severity of their condition:

  1. Classic Form: In the classic form of Farber’s disease, the prognosis is generally poor. Most children with this form do not survive past the age of 2, primarily due to complications arising from lung disease. The rapid progression of symptoms and the impact on critical organ systems, particularly the lungs, lead to this unfortunate outcome.
  2. Most Severe Form: Children born with the most severe form of Farber’s disease face an even more challenging prognosis. Typically, they may not survive beyond the first 6 months of life. This immediate severity often results from a combination of extreme symptoms, including rapid neurological deterioration and significant organ involvement.
  3. Milder Forms: In contrast, individuals with milder forms of Farber’s disease can have a longer lifespan, potentially living into their teenage years. The symptoms in these cases are less aggressive and progress more slowly, allowing for a longer period of survival.

The wide range in the severity and progression of Farber’s disease underscores the importance of early and accurate diagnosis, as well as the need for supportive care tailored to the specific needs of each patient. Despite advances in symptom management and supportive therapies, the prognosis remains challenging for many affected by this condition.

Call now to make an appointment